CRMD May 2024 6.000 call
| Previous close | 0.2500 |
| Open | 0.3500 |
| Bid | 0.3500 |
| Ask | 0.4500 |
| Strike | 6.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3100 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 448 |
GlobeNewswireCorMedix Inc. Announces CMS Grants TDAPA to DefenCath
BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® meets the criteria for a Transitional Drug Add-On Payment (TDAPA) in the anti-infective functional category, beginning on July 1, 2024. The TDAPA program currently provides
- GlobeNewswire
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced DefenCath® (taurolidine and heparin) catheter lock solution (CLS) is now commercially available for U.S. inpatient use. DefenCath (taurolidine and heparin) is approved by the U.S. Food and Drug Administration (FDA) to reduce the incidence of catheter-related
- GlobeNewswire
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that two abstracts have been accepted for presentation at the Society for Healthcare Epidemiology of America (SHEA) conference being held in Houston, Texas, April 16 – 19, 2024. The first abstract being presented examines in vitro antimicrobial activity of taurolidine against a
